加速期或酪氨酸激酶抑制剂治疗失败的慢性髓性白血病患者中的无治疗缓解
研究纳入60例有加速期病史(含原发加速期19例、转化为加速期4例)或慢性期酪氨酸激酶抑制剂(TKI)治疗失败(37例)后停用TKI的慢性髓性白血病(CML)患者。停用TKI后中位随访21个月,19例(31%)丧失主要分子学反应(MMR),3年持续MMR概率为59%(95%CI 45%-78%)。多因素分析显示停药时年龄<32岁(HR=4.1,P=0.014)和TKI治疗12个月时BCR::ABL1>0.1%(HR=3.9,P=0.011)与MMR丧失风险升高显著相关。
要点
- 有加速期病史或TKI治疗失败的CML患者,在足够TKI疗程和持续深度分子学反应后可尝试无治疗缓解。
- 停用TKI后中位随访21个月,19例(31%)丧失MMR,3年持续MMR概率为59%(95%CI 45%-78%)。
- 停药时年龄<32岁和TKI治疗12个月时BCR::ABL1>0.1%与MMR丧失风险升高显著相关。
核心结论
- 有加速期病史或TKI治疗失败的CML患者,在足够TKI疗程和持续深度分子学反应后可能成功实现无治疗缓解。
研究设计与样本
- 研究纳入60例停用TKI的CML患者,包括有加速期病史者(原发加速期19例、转化为加速期4例)和慢性期TKI治疗失败者37例。
主要发现
- 从诊断加速期或TKI治疗失败至达到深度分子学反应的中位间隔为19个月(IQR 9-30个月)。
- 中位TKI治疗时间和深度分子学反应持续时间分别为108个月(IQR 72-137个月)和59个月(IQR 39-87个月)。
- 停用TKI后中位随访21个月(IQR 11-36个月),19例(31%)丧失主要分子学反应(MMR),3年持续MMR概率为59%(95%CI 45%-78%)。
- 多因素分析中,停药时年龄<32岁(HR=4.1,95%CI 1.3-12.7,P=0.014)和TKI治疗12个月时BCR::ABL1>0.1%(参照≤0.1%;HR=3.9,95%CI 1.4-11.5,P=0.011)与TKI停药后MMR丧失概率升高显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We studied 60 chronic myeloid leukaemia (CML) patients with a prior history of accelerated phase (AP) including de novo AP (n = 19) and transformation to AP (n = 4), or tyrosine kinase inhibitor (TKI) therapy failure in the chronic phase (CP, n = 37), who discontinued TKI therapy. Median interval from diagnosis with AP or TKI therapy failure to achieving a deep molecular response (DMR) was 19 months (interquartile range [IQR], 9-30 months). Median TKI treatment and DMR duration were 108 months (IQR, 72-137 months) and 59 months (IQR, 39-87 months) respectively. At a median follow-up of 21 months (IQR, 11-36 months) after TKI discontinuation, 19 (31%) patients lost the major molecular response (MMR). The 3-year probability of a sustained MMR was 59% (95% confidence interval [CI], [45%, 78%]). In the multivariable analyses, age at discontinuation <32 years (hazard ratio [HR] = 4.1 [1.3, 12.7], p = 0.014) and BCR::ABL1 >0.1% at 12 months on TKI therapy (reference, ≤0.1%; HR = 3.9 [1.4, 11.5], p = 0.011) were significantly associated with a higher probability of MMR loss after TKI discontinuation. CML patients with a history of AP or TKI therapy failure may achieve successful treatment-free remission after an adequate TKI therapy duration and a sustained DMR.
引用
- Yuan M, Zhang Y, Liu B, et al. Treatment-free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure. Br J Haematol. 2025. PMID: 40799021. doi:10.1111/bjh.70080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。